GlobeNewswire by notified

Wolters Kluwer names Dave Guarino VP Global Communications

Share

Wolters Kluwer names Dave GuarinoVP Global Communications

April 01, 2022 — Wolters Kluwer (AEX: WKL), a global leading provider of expert solutions, insights and services for professionals, today announced the appointment of Dave Guarino as Vice President, Global Communications. Based in New York, Mr. Guarino will have overall communications responsibility for the Dutch-based technology company.

"We are thrilled that Dave has joined Wolters Kluwer in this key, newly created role,” said Caroline Wouters, SVP and Chief Corporate Brand and Communications Officer. “He comes at the perfect moment to drive global communications efforts that advance our recently announced three-year company strategy, Elevate our Value. With his extensive global experience, Dave will be instrumental in executing the company’s strategic priorities and identifying new opportunities in both internal and external communications.”

Mr. Guarino has a strong track record as an innovative communications leader in large global organizations. He joins Wolters Kluwer from S&P Global, a leading data and information services company, where he served as Chief Communications Officer. Prior to holding senior communications roles within S&P, Mr. Guarino worked at UBS and the New York Life Insurance Company. He holds a Bachelor of Science degree from The University of Scranton.

“For 186 years, Wolters Kluwer’s products and services have served as the backbone for smart and more insightful decision making,” said Mr. Guarino. “And today, this pioneering spirit is embedded not just within the company culture, but in how its groundbreaking innovations impact lives and shape society. I’m honored to join the many great innovators and leaders at Wolters Kluwer as we continue to enhance the way professionals do business and solve their most complex problems.”

About Wolters Kluwer
Wolters Kluwer is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on LinkedInTwitter, Facebook, and YouTube.

Media Contacts

Erica Glass (US) Gerbert van Genderen Stort (Europe/Asia)
Corporate Communications Corporate Communications
Tel: (516) 238-2280 Tel: +31 172 64 1230
press@wolterskluwer.compress@wolterskluwer.com

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation: general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Certain trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 202419.4.2024 13:00:00 CEST | Press release

The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers

NetBet Casino slår sig sammen med Stakelogic19.4.2024 12:59:43 CEST | pressemeddelelse

COPENHAGEN, Denmark, April 19, 2024 (GLOBE NEWSWIRE) -- NetBet og Stakelogic har indgået en samarbejdsaftale, som vil bringe Stakelogics spil til NetBets kunder i Danmark. Selvom Stakelogic først blev grundlagt i 2014, har de hurtigt etableret sig som en stor spiller inden for online gaming. Deres omdømme som en nyskaber i branchen er blevet anerkendt, og virksomheden er blevet nomineret til de prestigefyldte kategorier, Industry Innovation of the Year, og Innovation in Casino Entertainment ved SBC Awards 2023. Blandt de mange spil, der er tilgængelige for NetBet Danmarks spillere som et resultat af partnerskabet med Stakelogic, er Book of Cleopatra Super Stake Edition, Volcano Deluxe og Bandits Thunder Link. NetBet Danmarks PR-manager, Claudia Georgevici, udtaler: "Hos NetBet forstår vi vigtigheden af at give vores spillere så mange unikke spil som muligt for at sikre, at de får den bedst mulige spiloplevelse. Stakelogic har et bibliotek af innovative spil, hvilket gør dem til den ide

NetBet Casino joins forces with Stakelogic19.4.2024 12:59:43 CEST | Press release

COPENHAGEN, Denmark, April 19, 2024 (GLOBE NEWSWIRE) -- NetBet and Stakelogic have finalised a collaborative agreement that will bring Stakelogic’s games to NetBet customers in the Danish region. Despite only being founded in 2014, Stakelogic has quickly established themselves as a major player in the world of online gaming. Their reputation as an industry disruptor has been recognised, with the company being shortlisted for the prestigious categories of Industry Innovation of the Year and Innovation in Casino Entertainment at the SBC Awards 2023. Among the many games that are available to NetBet Denmark customers as a result of the partnership with Stakelogic are Book of Cleopatra Super Stake Edition, Volcano Deluxe and Bandits Thunder Link. NetBet Denmark’s PR manager, Claudia Georgevici, said: “At NetBet, we understand the importance of providing our players with as many unique games as possible, to ensure they have the best possible gaming experience. Stakelogic has a library of in

Giambattista Valli dazzles Barcelona during the Bridal Night19.4.2024 12:41:00 CEST | Press release

BARCELONA, Spain, April 19, 2024 (GLOBE NEWSWIRE) -- The most exclusive fashion show of the Barcelona Bridal Fashion Week charmed over 450 guests last night who enjoyed a unique show in the historic building of the Llotja de Mar. The Maison Giambattista Valli exclusively celebrated the runway debut of its bridal collection during the Bridal Night, the gala evening of the event organized by Fira de Barcelona with the support of the Catalan Ministry of Business and Labor. In an extraordinary show, Giambattista Valli's 30 creations shone with their own light. It was a culmination of silhouettes, representing a comprehensive exhibition of Mr. Valli’s concept of contemporary bridal dressing, inviting his audience to witness the manifestation of his vision, translated into a presentation that embodies the essence of individuality, sharing a dream and a celebration and love. The fashion show featured ten dresses from the third “Love Collection,” ten iconic silhouettes from the first and secon

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T

HiddenA line styled icon from Orion Icon Library.Eye